-0.83%
6.39%
2.57%
-2.30%
-16.45%
-30.63%
-40.44%
AI Spotlight on EKTA
Company Description
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide.The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology.It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment.
In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery.Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery.The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
Market Data
| Last Price | 65.75 |
| Change Percentage | -0.83% |
| Open | 66.6 |
| Previous Close | 66.3 |
| Market Cap ( Millions) | 24137 |
| Volume | 736049 |
| Year High | 88.85 |
| Year Low | 58.2 |
| M A 50 | 62.62 |
| M A 200 | 68.26 |
Financial Ratios
| FCF Yield | 2.41% |
| Dividend Yield | 5.48% |
| ROE | 9.51% |
| Debt / Equity | 89.16% |
| Net Debt / EBIDTA | 234.61% |
| Price To Book | 2.43 |
| Price Earnings Ratio | 25.29 |
| Price To FCF | 41.47 |
| Price To sales | 1.36 |
| EV / EBITDA | 11.88 |
News
- Jan -03 - Discover AlphaCorp And 2 Other Stocks That May Be Priced Below Their Estimated Value
- Nov -29 - 3 Stocks That May Be Priced Below Their Estimated Worth In November 2024
- Nov -28 - Elekta AB (EKTAF) Q2 2025 Earnings Call Highlights: Navigating Challenges with Strategic Innovations
- Aug -28 - Elekta's Q1 beats estimates, shares jump
- Jun -05 - Elekta shares slump after weaker-than-anticipated fourth-quarter earnings
- May -06 - Elekta introduces AI-powered adaptive CT-Linac
- Apr -23 - GE HealthCare's (GEHC) New Tie-Up to Boost Patient Outcomes
- Apr -23 - GE Healthcare subsidiary expands radiation therapy partnership with Elekta
- Oct -27 - Is Phillips 66 (PSX) Stock Undervalued Right Now?
Business Breakdown
Expected Mid-Term Growth
Segment n°1 -> Hardware
Expected Growth : 5 %
What the company do ?
Elekta AB (publ) is a Swedish company that develops and sells medical equipment for treating cancer and brain disorders, including linear accelerators and radiosurgery systems.
Why we expect these perspectives ?
Elekta AB's 5% growth in Hardware segment is driven by increasing demand for radiation therapy and oncology solutions, expansion into emerging markets, and strategic partnerships. Additionally, advancements in digitalization and automation of cancer care, as well as growing adoption of stereotactic body radiation therapy (SBRT) and brachytherapy, contribute to the segment's growth.
Segment n°2 -> Services (Including Software)
Expected Growth : 7 %
What the company do ?
Elekta AB (publ) provides radiation therapy and oncology services, including software for cancer treatment planning, radiation therapy management, and medical imaging analysis.
Why we expect these perspectives ?
Elekta AB's 7% growth in Services (Including Software) is driven by increasing demand for cancer treatment and radiation therapy, expansion into emerging markets, and strategic partnerships. Additionally, the company's software solutions, such as Monaco and MOSAIQ, are experiencing high adoption rates, contributing to the segment's growth.
Segment n°3 -> Software
Expected Growth : 5 %
What the company do ?
Elekta AB (publ) develops and sells radiation therapy and oncology informatics solutions for cancer care, enabling precise and effective treatment.
Why we expect these perspectives ?
Elekta AB's software segment growth is driven by increasing demand for cancer treatment and radiation therapy, adoption of digital healthcare, and strategic partnerships. The company's innovative solutions, such as Monaco and Unity, are gaining traction, while expansion into emerging markets and growing recurring revenue streams also contribute to the 5% growth rate.
Elekta Ab (Publ) Products
| Product Range | What is it ? |
|---|---|
| Gamma Knife Icon | A non-invasive radiosurgery system for treating brain disorders and cancer |
| Elekta Unity | A high-field magnetic resonance imaging (MRI) guided radiation therapy system |
| Versa HD | A high-definition dynamic radiosurgery system for treating cancer and brain disorders |
| Monaco Treatment Planning System | A radiation therapy treatment planning system for cancer treatment |
| MOSAIQ Oncology Information System | A comprehensive oncology information system for managing patient data and treatment plans |
| EstroCare | A patient-centric software solution for managing radiation therapy treatment plans |
Elekta AB (publ)'s Porter Forces
Threat Of Substitutes
Elekta AB (publ) operates in a niche market with high barriers to entry, reducing the threat of substitutes. However, the company's products and services can be substituted with alternative treatments, such as surgery or chemotherapy, which poses a moderate threat.
Bargaining Power Of Customers
Elekta AB (publ) has a diverse customer base, including hospitals and cancer centers, which reduces the bargaining power of individual customers. Additionally, the company's products and services are often critical to customers' operations, making it difficult for them to negotiate prices.
Bargaining Power Of Suppliers
Elekta AB (publ) relies on a few key suppliers for critical components, which gives them some bargaining power. However, the company's large size and global presence also give it some negotiating power, mitigating the threat.
Threat Of New Entrants
The radiation therapy market has high barriers to entry, including significant capital expenditures and regulatory hurdles, making it difficult for new entrants to join the market.
Intensity Of Rivalry
The radiation therapy market is highly competitive, with a few large players competing for market share. Elekta AB (publ) faces intense competition from companies like Varian Medical Systems and Siemens Healthineers, which can lead to pricing pressure and increased marketing expenses.
Capital Structure
| Value | |
|---|---|
| Debt Weight | 40.67% |
| Debt Cost | 4.30% |
| Equity Weight | 59.33% |
| Equity Cost | 9.07% |
| WACC | 7.13% |
| Leverage | 68.54% |
Elekta AB (publ) : Quality Control
Elekta AB (publ) passed 2 out of 9 key points:
Historical Valuation
Price/Earnings Ratio
Margin Valuation
Peers Valuation
Competitors
| Company | Rational |
|---|---|
| TECN.SW | Tecan Group AG provides laboratory instruments and solutions for pharmaceutical and biotechnology companies, university research departments, and forensic and diagnostic laboratories. It operates through Life Sciences Business and Partnering Business … |
| YPSN.SW | Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for pharmaceutical and biotechnology companies. The company operates in two segments, Ypsomed Delivery Systems and … |
| AMP.MI | Amplifon S.p.A. retails hearing care products and services that help people rediscover various emotions of sound. The company offers ampli-easy, ampli-mini, ampli-connect, and ampli-energy hearing devices. It also provides fitting … |
| CTEC.L | ConvaTec Group Plc develops, manufactures, and markets medical products and technologies worldwide. It offers advanced wound dressings and skin care products for the management of acute and chronic wounds resulting … |
| FIE.DE | Fielmann Aktiengesellschaft, together with its subsidiaries, engages in the investment in and operation of optical and hearing aid businesses. The company manufactures and sells visual aids and other optical products, … |
Peers Metrics
DCF BETA
Expected Cash-Flows
Scoring Insights
Peers Group Analysis
🥇
Fielmann
A-Score
1-Year Total Return ->
🥈
Elekta
A-Score
1-Year Total Return ->
🥉
Ypsomed
A-Score
1-Year Total Return ->
4
ConvaTec
A-Score
1-Year Total Return ->
5
Amplifon
A-Score
1-Year Total Return ->
6
